

Mirtazapine Solid Formulation

Version 3.11 Revision Date: 23.03.2020 SDS Number: 50166-00015 Date of last issue: 13.09.2019
Date of first issue: 23.01.2015

Section 1: Identification

Product name : Mirtazapine Solid Formulation

Manufacturer or supplier's details

Company : Organon & Co.

Address : 30 Hudson Street, 33nd floor
Jersey City, New Jersey, U.S.A 07302

Telephone : 551-430-6000

Emergency telephone number : 215-631-6999

E-mail address : EHSSTEWARD@organon.com

Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical

Section 2: Hazard identification**GHS Classification**

Reproductive toxicity : Repr.2

Specific target organ toxicity - repeated exposure (Oral) : STOT RE2 (Nervous system)

GHS label elements

Hazard pictograms :



Signal word : Warning

Hazard statements : H361fd Suspected of damaging fertility. Suspected of damaging the unborn child.
H373 May cause damage to organs (Nervous system) through prolonged or repeated exposure if swallowed.

Precautionary statements : **Prevention:**
P201 Obtain special instructions before use.
P202 Do not handle until all safety precautions have been read and understood.
P260 Do not breathe dust.
P281 Use personal protective equipment as required.
Response:
P308 + P313 IF exposed or concerned: Get medical advice/attention.

Mirtazapine Solid Formulation

Version 3.11 Revision Date: 23.03.2020 SDS Number: 50166-00015 Date of last issue: 13.09.2019
Date of first issue: 23.01.2015

Storage:

P405 Store locked up.

Disposal:

P501 Dispose of contents/ container to an approved waste disposal plant.

Other hazards which do not result in classification

Dust contact with the eyes can lead to mechanical irritation.

Contact with dust can cause mechanical irritation or drying of the skin.

May form explosive dust-air mixture during processing, handling or other means.

Section 3: Composition/information on ingredients

Substance / Mixture : Mixture

Components

Chemical name	CAS-No.	Concentration (% w/w)
(+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine	85650-52-8	>= 10 -< 30
Starch	9005-25-8	>= 10 -< 30

Section 4: First-aid measures

- General advice : In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical advice.
- If inhaled : If inhaled, remove to fresh air.
Get medical attention.
- In case of skin contact : In case of contact, immediately flush skin with soap and plenty of water.
Remove contaminated clothing and shoes.
Get medical attention.
Wash clothing before reuse.
Thoroughly clean shoes before reuse.
- In case of eye contact : If in eyes, rinse well with water.
Get medical attention if irritation develops and persists.
- If swallowed : If swallowed, DO NOT induce vomiting.
Get medical attention.
Rinse mouth thoroughly with water.
- Most important symptoms and effects, both acute and delayed : Suspected of damaging fertility. Suspected of damaging the unborn child.
May cause damage to organs through prolonged or repeated exposure if swallowed.
Contact with dust can cause mechanical irritation or drying of the skin.
- Protection of first-aiders : Dust contact with the eyes can lead to mechanical irritation.
First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Mirtazapine Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 13.09.2019
3.11	23.03.2020	50166-00015	Date of first issue: 23.01.2015

Notes to physician : Treat symptomatically and supportively.

Section 5: Fire-fighting measures

Suitable extinguishing media : Water spray
Alcohol-resistant foam
Carbon dioxide (CO₂)
Dry chemical

Unsuitable extinguishing media : None known.

Specific hazards during fire-fighting : Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard.
Exposure to combustion products may be a hazard to health.

Hazardous combustion products : Carbon oxides
Silicon oxides

Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Use water spray to cool unopened containers.
Remove undamaged containers from fire area if it is safe to do so.
Evacuate area.

Special protective equipment for firefighters : In the event of fire, wear self-contained breathing apparatus.
Use personal protective equipment.

Section 6: Accidental release measures

Personal precautions, protective equipment and emergency procedures : Use personal protective equipment.
Follow safe handling advice and personal protective equipment recommendations.

Environmental precautions : Discharge into the environment must be avoided.
Prevent further leakage or spillage if safe to do so.
Retain and dispose of contaminated wash water.
Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up : Sweep up or vacuum up spillage and collect in suitable container for disposal.
Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).
Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

Section 7: Handling and storage

Mirtazapine Solid Formulation

Version 3.11 Revision Date: 23.03.2020 SDS Number: 50166-00015 Date of last issue: 13.09.2019
Date of first issue: 23.01.2015

- Technical measures : Static electricity may accumulate and ignite suspended dust causing an explosion.
Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.
- Local/Total ventilation : Use only with adequate ventilation.
- Advice on safe handling : Do not breathe dust.
Do not swallow.
Avoid contact with eyes.
Avoid prolonged or repeated contact with skin.
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment
Minimize dust generation and accumulation.
Keep container closed when not in use.
Keep away from heat and sources of ignition.
Take precautionary measures against static discharges.
Take care to prevent spills, waste and minimize release to the environment.
- Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.
When using do not eat, drink or smoke.
Wash contaminated clothing before re-use.
- Conditions for safe storage : Keep in properly labelled containers.
Store locked up.
Store in accordance with the particular national regulations.
- Materials to avoid : Do not store with the following product types:
Strong oxidizing agents

Section 8: Exposure controls/personal protection

Components with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
(+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine	85650-52-8	TWA	25 µg/m ³	Internal
		Wipe limit	250 µg/100 cm ²	Internal
Starch	9005-25-8	WES-TWA	10 mg/m ³	NZ OEL
		TWA	10 mg/m ³	ACGIH

- Engineering measures** : Ensure adequate ventilation, especially in confined areas.
Minimize workplace exposure concentrations.
Apply measures to prevent dust explosions.
Ensure that dust-handling systems (such as exhaust ducts, dust collectors, vessels, and processing equipment) are designed in a manner to prevent the escape of dust into the work area (i.e., there is no leakage from the equipment).

Personal protective equipment

- Respiratory protection : If adequate local exhaust ventilation is not available or expo-

Mirtazapine Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 13.09.2019
3.11	23.03.2020	50166-00015	Date of first issue: 23.01.2015

	sure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.
Filter type	: Particulates type
Hand protection	
Material	: Chemical-resistant gloves
Remarks	: Choose gloves to protect hands against chemicals depending on the concentration and quantity of the hazardous substance and specific to place of work. Breakthrough time is not determined for the product. Change gloves often! For special applications, we recommend clarifying the resistance to chemicals of the aforementioned protective gloves with the glove manufacturer. Wash hands before breaks and at the end of workday.
Eye protection	: Wear the following personal protective equipment: Safety goggles
Skin and body protection	: Select appropriate protective clothing based on chemical resistance data and an assessment of the local exposure potential. Skin contact must be avoided by using impervious protective clothing (gloves, aprons, boots, etc).

Section 9: Physical and chemical properties

Appearance	: powder
Colour	: No data available
Odour	: No data available
Odour Threshold	: No data available
pH	: No data available
Melting point/freezing point	: No data available
Initial boiling point and boiling range	: No data available
Flash point	: Not applicable
Evaporation rate	: No data available
Flammability (solid, gas)	: May form explosive dust-air mixture during processing, handling or other means.
Flammability (liquids)	: No data available
Upper explosion limit / Upper flammability limit	: No data available
Lower explosion limit / Lower flammability limit	: No data available

SAFETY DATA SHEET



Mirtazapine Solid Formulation



Version 3.11 Revision Date: 23.03.2020 SDS Number: 50166-00015 Date of last issue: 13.09.2019
Date of first issue: 23.01.2015

Vapour pressure : No data available

Relative vapour density : No data available

Relative density : No data available

Density : No data available

Solubility(ies)
Water solubility : No data available

Partition coefficient: n-octanol/water : No data available

Auto-ignition temperature : No data available

Decomposition temperature : No data available

Viscosity
Viscosity, dynamic : No data available
Viscosity, kinematic : No data available

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Molecular weight : No data available

Particle size : No data available

Section 10: Stability and reactivity

Reactivity : Not classified as a reactivity hazard.

Chemical stability : Stable under normal conditions.

Possibility of hazardous reactions : May form explosive dust-air mixture during processing, handling or other means.
Can react with strong oxidizing agents.

Conditions to avoid : Heat, flames and sparks.
Avoid dust formation.

Incompatible materials : Oxidizing agents

Hazardous decomposition products : No hazardous decomposition products are known.

Section 11: Toxicological information

Exposure routes : Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity

Not classified based on available information.

Mirtazapine Solid Formulation

Version 3.11 Revision Date: 23.03.2020 SDS Number: 50166-00015 Date of last issue: 13.09.2019
Date of first issue: 23.01.2015

Product:

Acute oral toxicity : Acute toxicity estimate: > 2,000 mg/kg
Method: Calculation method

Components:**(+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:**

Acute oral toxicity : LD50 (Rat): 320 - 490 mg/kg

Starch:

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg

Skin corrosion/irritation

Not classified based on available information.

Serious eye damage/eye irritation

Not classified based on available information.

Components:**Starch:**

Species : Rabbit
Result : No eye irritation

Respiratory or skin sensitisation**Skin sensitisation**

Not classified based on available information.

Respiratory sensitisation

Not classified based on available information.

Components:**Starch:**

Test Type : Maximisation Test
Exposure routes : Skin contact
Species : Guinea pig
Result : negative

Chronic toxicity**Germ cell mutagenicity**

Not classified based on available information.

Components:**(+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:**

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Mirtazapine Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 13.09.2019
3.11	23.03.2020	50166-00015	Date of first issue: 23.01.2015

Test Type: In vitro mammalian cell gene mutation test
 Test system: Chinese hamster lung cells
 Result: negative

Test Type: unscheduled DNA synthesis assay
 Test system: mammalian cells
 Result: negative

Test Type: sister chromatid exchange assay
 Test system: mammalian cells
 Result: negative

Genotoxicity in vivo : Test Type: Micronucleus test
 Species: Rat
 Cell type: Bone marrow
 Application Route: Oral
 Result: negative

Starch:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
 Result: negative

Carcinogenicity

Not classified based on available information.

Components:**(+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:**

Species : Mouse
 Application Route : Oral
 Exposure time : 18 month(s)
 LOAEL : 200 mg/kg body weight
 Result : equivocal
 Target Organs : Liver

Species : Rat
 Application Route : Oral
 Exposure time : 2 Years
 LOAEL : 20 mg/kg body weight
 Result : equivocal
 Target Organs : Liver, Thyroid

Reproductive toxicity

Suspected of damaging fertility. Suspected of damaging the unborn child.

Components:**(+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:**

Effects on fertility : Test Type: Fertility/early embryonic development
 Species: Rat
 Application Route: Oral
 Fertility: LOAEL: 15 mg/kg body weight
 Symptoms: Effect on estrous cycle, Increase of early resorptions

Mirtazapine Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 13.09.2019
3.11	23.03.2020	50166-00015	Date of first issue: 23.01.2015

Result: Animal testing did not show any effects on fertility., Embryotoxic effects and adverse effects on the offspring were detected.

Effects on foetal development : Test Type: Development
Species: Rat
Application Route: Oral
Developmental Toxicity: LOAEL: 100 mg/kg body weight
Result: Embryotoxic effects and adverse effects on the offspring were detected., No teratogenic effects

Test Type: Development
Species: Rabbit
Application Route: Oral
Developmental Toxicity: NOAEL: 40 mg/kg body weight
Result: No adverse effects, No teratogenic effects

Reproductive toxicity - Assessment : Some evidence of adverse effects on sexual function and fertility, based on animal experiments., Some evidence of adverse effects on development, based on animal experiments.

STOT - single exposure

Not classified based on available information.

STOT - repeated exposure

May cause damage to organs (Nervous system) through prolonged or repeated exposure if swallowed.

Components:**(+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:**

Exposure routes : Ingestion
Target Organs : Nervous system
Assessment : May cause damage to organs through prolonged or repeated exposure.

Repeated dose toxicity**Components:****(+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:**

Species : Rat
LOAEL : 120 mg/kg
Application Route : Oral
Exposure time : 13 Weeks
Target Organs : Nervous system

Species : Dog
LOAEL : 15 mg/kg
Application Route : Oral
Exposure time : 52 Weeks
Target Organs : Nervous system
Symptoms : Tremors

Mirtazapine Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 13.09.2019
3.11	23.03.2020	50166-00015	Date of first issue: 23.01.2015

Species	:	Dog
LOAEL	:	20 mg/kg
Application Route	:	Oral
Exposure time	:	13 Weeks
Target Organs	:	Nervous system, Testis
Symptoms	:	Tremors

Starch:

Species	:	Rat
NOAEL	:	>= 2,000 mg/kg
Application Route	:	Skin contact
Exposure time	:	28 Days
Method	:	OECD Test Guideline 410

Aspiration toxicity

Not classified based on available information.

Experience with human exposure**Components:****(+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:**

Ingestion	:	Symptoms: Drowsiness, constipation, dry mouth, asthenia, Dizziness, Disorientation
-----------	---	------------------------------------------------------------------------------------

Section 12: Ecological information**Ecotoxicity****Components:****(+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:**

Toxicity to fish	:	LC50 (Pimephales promelas (fathead minnow)): 6.92 mg/l Exposure time: 96 h Method: FDA 4.11
------------------	---	---------------------------------------------------------------------------------------------------

Toxicity to daphnia and other aquatic invertebrates	:	EC50 (Daphnia magna (Water flea)): 19.5 mg/l Exposure time: 48 h
-----------------------------------------------------	---	---------------------------------------------------------------------

Toxicity to algae/aquatic plants	:	EC50 (Pseudokirchneriella subcapitata (green algae)): 5.7 mg/l Exposure time: 72 h Method: OECD Test Guideline 201
----------------------------------	---	--------------------------------------------------------------------------------------------------------------------------

	:	NOEC (Pseudokirchneriella subcapitata (green algae)): 3.2 mg/l Exposure time: 72 h Method: OECD Test Guideline 201
--	---	--------------------------------------------------------------------------------------------------------------------------

Toxicity to fish (Chronic toxicity)	:	NOEC (Pimephales promelas (fathead minnow)): 3.6 mg/l Exposure time: 31 d Method: OECD Test Guideline 210
-------------------------------------	---	-----------------------------------------------------------------------------------------------------------------

Toxicity to daphnia and other	:	NOEC (Daphnia magna (Water flea)): 0.32 mg/l
-------------------------------	---	----------------------------------------------

Mirtazapine Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 13.09.2019
3.11	23.03.2020	50166-00015	Date of first issue: 23.01.2015

aquatic invertebrates (Chronic toxicity) : Exposure time: 21 d
Method: OECD Test Guideline 211

Toxicity to microorganisms : EC50 (Natural microorganism): > 1,000 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209

NOEC (Natural microorganism): < 100 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209

Persistence and degradability

No data available

Bioaccumulative potential**Components:****(+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:**

Bioaccumulation : Species: Oncorhynchus mykiss (rainbow trout)
Bioconcentration factor (BCF): 334
Method: OECD Test Guideline 305

Partition coefficient: n-octanol/water : log Pow: 2.78

Mobility in soil**Components:****(+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:**

Distribution among environmental compartments : log Koc: 4.48

Other adverse effects

No data available

Section 13: Disposal considerations**Disposal methods**

Waste from residues : Dispose of in accordance with local regulations.
Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

Section 14: Transport information**International Regulations****UNRTDG**

Not regulated as a dangerous good

IATA-DGR

Not regulated as a dangerous good

Mirtazapine Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 13.09.2019
3.11	23.03.2020	50166-00015	Date of first issue: 23.01.2015

IMDG-Code

Not regulated as a dangerous good

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

National Regulations**NZS 5433**

Not regulated as a dangerous good

Section 15: Regulatory information**Safety, health and environmental regulations/legislation specific for the substance or mixture****HSNO Approval Number**

HSR100425 Pharmaceutical Active Ingredients Group Standard 2017

HSW Controls

Certified handler certificate not required.

Tracking hazardous substance not required.

Refer to the Health and Safety at Work (Hazardous Substances) Regulations 2017, for further information.

The components of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

Section 16: Other information**Further information**Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Date format : dd.mm.yyyy

Full text of other abbreviations

ACGIH : USA. ACGIH Threshold Limit Values (TLV)

NZ OEL : New Zealand. Workplace Exposure Standards for Atmospheric Contaminants

ACGIH / TWA : 8-hour, time-weighted average

NZ OEL / WES-TWA : Workplace Exposure Standard - Time Weighted average

AICS - Australian Inventory of Chemical Substances; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for

SAFETY DATA SHEET



Mirtazapine Solid Formulation



Version	Revision Date:	SDS Number:	Date of last issue: 13.09.2019
3.11	23.03.2020	50166-00015	Date of first issue: 23.01.2015

Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

NZ / EN